Milestone Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Milestone Pharmaceuticals's estimated annual revenue is currently $15M per year.
- Milestone Pharmaceuticals received $80.0M in venture funding in October 2018.
- Milestone Pharmaceuticals's estimated revenue per employee is $185,185
- Milestone Pharmaceuticals's total funding is $174M.
- Milestone Pharmaceuticals's current valuation is $246.1M. (January 2022)
Employee Data
- Milestone Pharmaceuticals has 81 Employees.
- Milestone Pharmaceuticals grew their employee count by 35% last year.
Milestone Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | COO | Reveal Email/Phone |
4 | VP Information Technology | Reveal Email/Phone |
5 | VP Medical Affairs | Reveal Email/Phone |
6 | VP, Communications | Reveal Email/Phone |
7 | VP Market Access | Reveal Email/Phone |
8 | VP Human Resources | Reveal Email/Phone |
9 | VP Market Access | Reveal Email/Phone |
10 | VP Regulatory Affairs | Reveal Email/Phone |
Milestone Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.9M | 77 | 7% | N/A | N/A |
#2 | $6221.7M | 40140 | -4% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $0.8M | 5 | -55% | N/A | N/A |
#5 | $2.8M | 18 | 6% | $11.1M | N/A |
#6 | $1M | 13 | -41% | N/A | N/A |
#7 | $1.7M | 11 | 0% | N/A | N/A |
#8 | $0.6M | 4 | 0% | N/A | N/A |
#9 | $5.9M | 38 | -5% | N/A | N/A |
#10 | $6.8M | 44 | 7% | N/A | N/A |
What Is Milestone Pharmaceuticals?
Milestone Pharmaceuticals Inc. is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. Milestone's lead product is a potent and short-acting nasally-delivered calcium channel antagonist for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT). The company's lead product, etripamil (MSP-2017), is in phase 3.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$174M
Total Funding
81
Number of Employees
$15M
Revenue (est)
35%
Employee Growth %
$246.1M
Valuation
N/A
Accelerator
Milestone Pharmaceuticals News
Should You Hold Milestone Pharmaceuticals Inc (MIST) in Biotechnology Industry? Tuesday, April 19, 2022 11:49 AM | InvestorsObserver Analysts.
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The...
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative...
MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, ...
Other Companies in Charlotte
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.3M | 81 | 59% | N/A |
#2 | $12.2M | 81 | 59% | N/A |
#3 | $21.9M | 81 | 8% | N/A |
#4 | $20.3M | 81 | 23% | N/A |
#5 | $28.6M | 81 | 9% | N/A |
Milestone Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-08-02 | $55.0M | C | Novo Holdings A/S | Article |
| 2018-10-26 | $80.0M | C | RTW Investments, LP | Article |